ArticleBlood advances2022

Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Ajlan Al Zaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.